{"id":"W4391786157","doi":"10.1007/s00262-023-03623-z","title":"INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"MacroGenics; AstraZeneca; Eli Lilly and Company; Astellas Pharma; Bristol-Myers Squibb","keywords":"Tremelimumab; Medicine; Tolerability; Discontinuation; Adverse effect; Oncology; Internal medicine; Response Evaluation Criteria in Solid Tumors; Cancer; Phases of clinical research; Clinical trial; Immunotherapy; Ipilimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004123206,0.0004773883,0.001082271,0.0007808985,0.0001193407,0.00005368287,0.0004684289,0.0001599187,0.0002930229],"category_scores_gemma":[0.00001249719,0.0003681539,0.0000541442,0.001704484,0.0003345668,0.0005116539,0.00008510277,0.0006369477,0.000003438249],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00081438,"about_ca_system_score_gemma":0.0007451019,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001511472,"about_ca_topic_score_gemma":0.00127471,"domain_scores_codex":[0.9971132,0.000193949,0.0009826559,0.0007552519,0.0003815789,0.0005733238],"domain_scores_gemma":[0.9985998,0.00007798415,0.0003160831,0.0007408995,0.000218658,0.00004657079],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2305612,0.03948887,0.08012408,0.0001639396,0.003243427,0.000198573,0.01465914,0.00007920349,0.09581117,0.00007935423,0.0001133914,0.5354777],"study_design_scores_gemma":[0.5394627,0.1146864,0.3191166,0.004475849,0.0001995324,0.00004378107,0.003668487,0.0001666075,0.01290363,0.00005827462,0.004168616,0.001049501],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807703,0.01434311,0.0000116827,0.0004340762,0.0004555568,0.003672035,0.00003246678,0.00007740693,0.0002033106],"genre_scores_gemma":[0.9966601,0.001466934,0.0001089878,0.0002984297,0.00002249889,0.001026072,0.00007371738,0.0001115083,0.0002317164],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5344282,"threshold_uncertainty_score":0.999877,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02397063968778328,"score_gpt":0.3438805567695655,"score_spread":0.3199099170817822,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}